Loading
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Latest quote
$9.53
−$0.12 · -1.24%
After-hours
$9.47
−$0.06 · -0.63%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Day range
Current $9.53
52-week range
Current $9.53
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
79
Undervalued
Sentiment
63
Bullish
Risk
47
Elevated Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Day range
Current $9.53
52-week range
Current $9.53
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 376.13M USD | 297.2M USD | 245.32M USD | 205.62M USD | 198.87M USD |
| Cost of goods sold | 45.5M USD | 35.4M USD | 25.21M USD | 17.56M USD | 21.14M USD |
| Gross profit | 330.63M USD | 261.8M USD | 220.1M USD | 188.06M USD | 177.73M USD |
| Research and development | 100.37M USD | 83.15M USD | 68.91M USD | 52.53M USD | 70.37M USD |
| Selling, general, and administrative | 117.44M USD | 99.22M USD | 87.5M USD | 68.85M USD | — |
| Operating expenses | 309.75M USD | 265.47M USD | 242.39M USD | 178.2M USD | 158.72M USD |
| Interest income | 2.18M USD | 5.92M USD | 3.53M USD | 85K USD | 59.99K USD |
| Interest expense | 10.72M USD | 9.05M USD | 5.96M USD | 5.36M USD | 7M USD |
| Depreciation and amortization | 11.22M USD | 16.07M USD | 15.93M USD | 13.19M USD | 19.61M USD |
| Operating income | 20.88M USD | −3.67M USD | −22.29M USD | 9.86M USD | 19.01M USD |
| Net income | 2.85M USD | −11.84M USD | −10.55M USD | 13.67M USD | 16M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$39.00
309.23% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
